97 related articles for article (PubMed ID: 2431765)
1. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines.
Nagle RB; Ahmann FR; McDaniel KM; Paquin ML; Clark VA; Celniker A
Cancer Res; 1987 Jan; 47(1):281-6. PubMed ID: 2431765
[TBL] [Abstract][Full Text] [Related]
2. Keratin immunoreactivity in the benign and neoplastic human prostate.
Brawer MK; Peehl DM; Stamey TA; Bostwick DG
Cancer Res; 1985 Aug; 45(8):3663-7. PubMed ID: 2410099
[TBL] [Abstract][Full Text] [Related]
3. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer.
Verhagen AP; Ramaekers FC; Aalders TW; Schaafsma HE; Debruyne FM; Schalken JA
Cancer Res; 1992 Nov; 52(22):6182-7. PubMed ID: 1384957
[TBL] [Abstract][Full Text] [Related]
4. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
5. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
7. Keratin patterns in prostatic hyperplasia and adenocarcinoma.
Svanholm H; Nielsen B; Starklint H
APMIS Suppl; 1988; 4():100-8. PubMed ID: 2465010
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
9. Expression of basal cell keratins in human prostate cancer metastases and cell lines.
van Leenders GJ; Aalders TW; Hulsbergen-van de Kaa CA; Ruiter DJ; Schalken JA
J Pathol; 2001 Dec; 195(5):563-70. PubMed ID: 11745692
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of prostate carcinoma on biopsy specimens improved by basal-cell-specific anti-cytokeratin antibody (34 beta E12).
Freibauer C
Wien Klin Wochenschr; 1998 Sep; 110(17):608-11. PubMed ID: 9816630
[TBL] [Abstract][Full Text] [Related]
11. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H; Remberger K
Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
[TBL] [Abstract][Full Text] [Related]
12. Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry.
Helpap B; Köllermann J; Oehler U
J Pathol; 2001 Mar; 193(3):350-3. PubMed ID: 11241415
[TBL] [Abstract][Full Text] [Related]
13. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
14. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
16. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.
Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO
Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
Hussein MR; Al-Assiri M; Musalam AO
Exp Mol Pathol; 2009 Apr; 86(2):108-13. PubMed ID: 19111537
[TBL] [Abstract][Full Text] [Related]
18. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines.
Webber MM; Bello D; Quader S
Prostate; 1996 Dec; 29(6):386-94. PubMed ID: 8977636
[TBL] [Abstract][Full Text] [Related]
19. Changes in keratin expression during the development of benign prostatic hyperplasia.
Xue Y; Smedts F; Umbas R; Aalders TW; Debruyne FM; de la Rosette JJ; Schalken JA
Eur Urol; 1997; 32(3):332-8. PubMed ID: 9358223
[TBL] [Abstract][Full Text] [Related]
20. [Suspicious acinar proliferations of the prostate].
Helpap B
Verh Dtsch Ges Pathol; 1999; 83():162-7. PubMed ID: 10714207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
